Abstract: Objective To discuss the regularity and characteristics of rituximab adverse reactions in clinical use, and to provide reference for clinical drug use. Methods A total of 56 ADR cases using rituximab were reported from 2006 to June 2017 in CNKI, Wanfang database and PUBMED. Then we analyzed the general condition, drug use and the incidence of ADR of patients. Results Of the 56 cases of ADR cases caused by rituximab, 34 cases (60.71%) were male patients, 22 cases (39.29%) were female patients, and the proportion of patients aged 60 to 69 was the largest (33.93%). The incidence of ADR mostly occurred in the intravenous infusion within 60 min and infusion within six months after the completion. The main clinical manifestations are respiratory damage and systemic damage. Conclusion We should pay attention to the ADR of rituximab clinically, and strengthen the monitoring of therapy, and adhere to the rational application.

Key words: rituximab, mabthera, adverse drug reaction